PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

被引：38

作者：

Banerjee, Susana ^{[2
]}

Kaye, Stan ^{[1
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Div Clin Studies, Inst Canc Res, Drug Dev Unit, Sutton SM2 5PT, Surrey, England

[2] Royal Marsden NHS Fdn Trust, Gynaecol Unit, Sutton SM2 5PT, Surrey, England

来源：

CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 06期

关键词：

PARP inhibitors; Ovarian cancer; BRCA; Olaparib; Endometrial; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; MUTANT-CELLS; TUMOR; MUTATIONS; CARCINOMA; FEATURES; DELETION; REPAIR;

D O I：

10.1007/s11912-011-0193-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.

引用

页码：442 / 449

页数：8

共 50 条

[41] Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations [J].

Pan, Yifang Eva ;

Hood, Annette ;

Ahmad, Hiba ;

Altwerger, Gary .

ANNALS OF PHARMACOTHERAPY, 2023, 57 (10) :1162-1171

[42] The BRCA Gene in Epithelial Ovarian Cancer [J].

Sanchez-Lorenzo, Luisa ;

Salas-Benito, Diego ;

Villamayor, Julia ;

Patino-Garcia, Ana ;

Gonzalez-Martin, Antonio .

CANCERS, 2022, 14 (05)

[43] PARP inhibitors in ovarian cancer: An overview of the practice-changing trials [J].

Foo, Tiffany ;

George, Angela ;

Banerjee, Susana .

GENES CHROMOSOMES & CANCER, 2021, 60 (05) :385-397

[44] PARP inhibitors in ovarian cancer: Mechanisms, resistance, and the promise of combination therapy [J].

Bhatia, Tejas ;

Doshi, Gaurav ;

Godad, Angel .

PATHOLOGY RESEARCH AND PRACTICE, 2024, 263 :155617

[45] Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer [J].

De Jaeghere, E. ;

Vandecasteele, K. ;

Claes, K. ;

Makar, A. ;

Tummers, P. ;

Cocquyt, V. ;

Denys, Hannelore .

ACTA CLINICA BELGICA, 2017, 72 (01) :6-11

[46] The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy [J].

Maiorano, Brigida Anna ;

Lorusso, Domenica ;

Maiorano, Mauro Francesco Pio ;

Ciardiello, Davide ;

Parrella, Paola ;

Petracca, Antonio ;

Cormio, Gennaro ;

Maiello, Evaristo .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)

[47] PARP inhibitors in the treatment of ovarian cancer [J].

Alain G. Zeimet ;

Verena Wieser ;

Katharina Knoll ;

Daniel Reimer ;

Christian Marth .

memo - Magazine of European Medical Oncology, 2020, 13 :198-201

[48] PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer [J].

Giannini, Andrea ;

Di Dio, Camilla ;

Di Donato, Violante ;

D'oria, Ottavia ;

Salerno, Maria Giovanna ;

Capalbo, Giuseppe ;

Cuccu, Ilaria ;

Perniola, Giorgia ;

Muzii, Ludovico ;

Bogani, Giorgio .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (09) :414-419

[49] What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? [J].

Joyce F. Liu ;

Ursula A. Matulonis .

Current Oncology Reports, 2016, 18

[50] Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents [J].

van Haaften, Caroline ;

van Eendenburg, Jaap ;

Boot, Arnoud ;

Corver, Willem E. ;

Haans, Lucien ;

van Wezel, Tom ;

Trimbos, J. Baptist .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (08) :1571-1578

← 1 2 3 4 5 →